In addition, according to a recent study, strengthening the expression of GPR39 with its agonist TC-G 1008 decreases the attachment of ox-LDL-challenged monocytes to endothelial cells, thus alleviating decelerating the development of atherosclerosis [17]. Here, GPR39 is linked to atherosclerosis.